Arrivent Biopharma Inc

AVBP is consolidating below its short- and intermediate-term moving averages, indicating a medium-term bearish bias. With price rejecting at the 9/20 EMA and 50-day SMA resistance zone, short-term conditions favor execution on rallies. Long-term support at the 200-day SMA remains, but the intermediate structure signals distribution and warrants selling into strength.

• ↑Moderate Buy consensus with $44.43 PT implies ~50% upside
• ↑Guggenheim and BTIG Buy ratings reinforce analyst confidence
• ↓Q2 reported $93M loss underscores ongoing cash burn